Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

Diabetes Obesity and Metabolism ◽

10.1111/dom.14272 ◽

2020 ◽

Author(s):

Carine Beysen ◽

Patricia Schroeder ◽

Eric Wu ◽

Julie Brevard ◽

Maria Ribadeneira ◽

...

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v1/review4 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v2/review1 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Decision letter for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v1/decision1 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v2/review3 ◽

2020 ◽

Author(s):

Jamie Bates

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v2/review2 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Decision letter for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v2/decision1 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v1/review3 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v1/review2 ◽

2020 ◽

Author(s):

Adrian Billeter

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v1/review1 ◽

2020 ◽

Author(s):

Loranne Agius

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

10.1111/dom.14272/v2/review4 ◽

2020 ◽

Keyword(s):

Fatty Acid ◽

Liver Disease ◽

Fatty Liver Disease ◽

Fatty Acid Synthase ◽

Randomized Trials ◽

De Novo ◽

De Novo Lipogenesis ◽

Alcoholic Fatty Liver ◽

Obese Subjects ◽

Alcoholic Fatty Liver Disease

Download Full-text